News & Perspective

Sep 15, 2017

Sep 15, 2017

ASP Scan (Weekly) for Sep 15, 2017

Promising novel assay
Transmissible Enterobacteriaceae
Additional FMT benefits
Antibiotic use and VRE infections
European AMR initiative
Antibiotic-resistant brucellosis
Drug-resistant gonorrhea Rx
ESBL bacteria in street kids
Funding for new C diff drug
Antimicrobial resistance in Africa
Antibiotics for asthmatic children
Drug resistance in the ICU

Mar 17, 2017

Mar 17, 2017

ASP Scan (Weekly) for Mar 17, 2017

Animal antibiotic use
Antibiotic-resistant eye infections
Antibiotic misconceptions
Sexual spread of resistant bacteria
New gram-negative antibiotic
MDRO screening, isolation

Feb 10, 2017

Feb 10, 2017

News Scan for Feb 10, 2017

Saudi MERS case
Senate confirms HHS pick
Avian flu update

Oct 27, 2014

Oct 27, 2014

CSL-Novartis deal includes US cell-based flu vaccine plant

The $275 million deal will make the company the second leading player in the $4 billion global flu vaccine market.

Nov 21, 2012

Nov 21, 2012

FDA clears first cell-based flu vaccine

(CIDRAP News) – The US Food and Drug Administration (FDA) yesterday approved the nation's first cell-based flu vaccine, a product from Novartis that uses technology that could help vaccinate more Americans in a pandemic but still has many of the same limitations of older egg-based flu vaccines.

Dec 13, 2011

Dec 13, 2011

Novartis says cell-based flu vaccine facility ready to produce

(CIDRAP News) – Novartis's new cell-culture based influenza vaccine factory in North Carolina has begun making a prepandemic H5N1 flu vaccine and is ready to start producing vaccines for a real pandemic when needed, the company and federal health officials announced yesterday.

The facility in Holly Springs, N.C., billed as the first of its kind in the United States, was dedicated yesterday after a long testing process.

Nov 24, 2009

Nov 24, 2009

Novartis unveils US cell-based flu vaccine plant

(CIDRAP News) – The era of cell-based influenza vaccine production in the United States seemed to move closer today as Novartis unveiled its new, nearly billion-dollar manufacturing plant in Holly Springs, N.C., but onshore production and marketing of cell-based vaccines remains a few years away.

Pages

Sort Results

 

Narrow results

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3M Gilead 
Grant support for ASP provided by

  Become an underwriter»